Found: 14
Select item for more details and to access through your institution.
Multivariate Modulation of the Zr MOF UiO‐66 for Defect‐Controlled Combination Anticancer Drug Delivery.
- Published in:
- Angewandte Chemie, 2020, v. 132, n. 13, p. 5249, doi. 10.1002/ange.201915848
- By:
- Publication type:
- Article
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response.
- Published in:
- AUANews, 2023, p. 23
- By:
- Publication type:
- Article
Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity.
- Published in:
- Current Oncology, 2022, v. 29, n. 4, p. 2530, doi. 10.3390/curroncol29040207
- By:
- Publication type:
- Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.
- Published in:
- Current Oncology, 2021, v. 28, n. 2, p. 1518, doi. 10.3390/curroncol28020143
- By:
- Publication type:
- Article
Multivariate Modulation of the Zr MOF UiO‐66 for Defect‐Controlled Combination Anticancer Drug Delivery.
- Published in:
- Angewandte Chemie International Edition, 2020, v. 59, n. 13, p. 5211, doi. 10.1002/anie.201915848
- By:
- Publication type:
- Article
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
- Published in:
- Oncologist, 2024, v. 29, n. 8, p. 699, doi. 10.1093/oncolo/oyae072
- By:
- Publication type:
- Article
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
- Published in:
- Oncologist, 2022, v. 27, n. 3, p. e286, doi. 10.1093/oncolo/oyac020
- By:
- Publication type:
- Article
Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
- Published in:
- Oncologist, 2020, v. 25, n. 5, p. 422, doi. 10.1634/theoncologist.2019-0605
- By:
- Publication type:
- Article
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 1, p. 1, doi. 10.1001/jamanetworkopen.2020.21869
- By:
- Publication type:
- Article
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 4, p. 1212, doi. 10.1002/cam4.3717
- By:
- Publication type:
- Article
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
- Published in:
- Prostate, 2014, v. 74, n. 15, p. 1544, doi. 10.1002/pros.22872
- By:
- Publication type:
- Article
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 6, p. e2216379, doi. 10.1001/jamanetworkopen.2022.16379
- By:
- Publication type:
- Article